AstraZeneca PLC (AZN.L)
| Previous close | 7,271.00 |
| Open | 7,252.00 |
| Bid | 7,404.00 x 0 |
| Ask | 7,404.00 x 0 |
| Day's range | 7,237.00 - 7,449.00 |
| 52-week range | 6,736.00 - 10,120.00 |
| Volume | 2,632,950 |
| Avg. volume | 3,055,780 |
| Market cap | 97.143B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 41.86 |
| EPS (TTM) | 176.80 |
| Earnings date | 30 Apr 2021 |
| Forward dividend & yield | 2.07 (2.80%) |
| Ex-dividend date | 25 Feb 2021 |
| 1y target est | 78.83 |
- Motley Fool
AstraZeneca's Vaccine Data Is Still Good Enough for U.S. Authorization
AstraZeneca (NASDAQ: AZN) created some drama releasing interim COVID-19 vaccine results just days before the pharma was able to generate final results from the U.S.-based phase 3 study. In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss the brouhaha, and what it means for AstraZeneca's long-term prospects. Brian Orelli: AstraZeneca reported a final data from its COVID-19 vaccine -- that it went from 79% efficacy at preventing symptomatic COVID-19 for the interim look and then at the final look it was 76%.
- Yahoo Finance UK
Moderna cuts UK COVID vaccine deliveries as pregnant women told mRNA jabs are safe
The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.
- Yahoo Finance Video
'You can think of it like an annual flu shot': Doctor on possible COVID-19 booster shots
Assistant Professor of Emergency Medicine at Baylor College of Medicine, Dr. Sara Andrabi, joined Yahoo Finance to break down her thoughts on the possibility of needing annual COVID-19 booster shots to.
